CMN Weekly (26 May 2023) - Your Weekly CRISPR Medicine News

Some of the best links we picked up around the internet

By: Gorm Palmgren - May. 26, 2023

#CRISPRMED24

Top picks

Research

  • Three new CRISPR gene editing systems that perform better than Cas9 are characterised by scientists at Metagenomi, California. The new CRISPR effector nucleases belong to type II (MG3-6 and a chimeric version MG3-6/4) and type V (MG29-1) and were sourced from the human microbiome and a hydrothermal vent, respectively. The authors find that all three systems can perform reproducible, high-frequency gene editing. e.g., disruption of the T cell receptor (TCR) alpha-chain was induced in >95% of cells, both paralogues of the TCR beta-chain in >90% of cells, and >90% knockout of β2-microglobulin, TIGIT, FAS, and PDCD1.
  • A new TALEN-based method enables efficient strand-selective base editing of human mitochondrial DNA. CRISPR-based strategies are hampered by the difficulty of delivering guide RNAs into mitochondria, while DNA binding in TALEN relies on highly variable amino acid sequences without additional guides. Circular RNAs encoding the mitoBEs delivered the tools into patient-derived cells, enabling up to 77% base-editing efficiency and high specificity in various pathogenic mitochondrial DNA mutations.
  • American scientists demonstrate CRISPR-based engineering of RNA viruses in a not-yet peer-reviewed paper. The authors combined sequence-specific VRISPR-based RNA cleavage with programmable RNA repair to make precise deletions and insertions in RNA. Approximately 5% of the bulk virus could be edited as intended.
  • Danish and Chinese researchers have compared the efficiency of three different gene editing techniques for the correction of Duchenne Muscular Dystrophy (DMN) mutations: in-frame deletion, homology-directed repair (HDR), and prime editing (PE). They find that the highest editing efficiency was achieved by non-homologous blunt end joining (NHBEJ, 74-77%), followed by HDR (21-24%) and PE2 (1.5%) in HEK293T cells.
  • A new versatile and efficient approach for precisely integrating large, gene-sized DNA fragments - LOCK - utilises specially designed 3'-overhang double-stranded DNA (odsDNA) donors harbouring 50-nt homology arm. LOCK allows highly efficient targeted insertion of kilobase-sized DNA fragments into the mammalian genomes with low cost and low off-target effects, yielding >fivefold higher knock-in frequencies than conventional homologous recombination-based approaches.

Industry

Detection

Reviews

News from CRISPR Medicine News

To get more of the CRISPR Medicine News delivered to your inbox, sign up to the free weekly CMN Newsletter here.

Tags

HashtagArticleHashtagMissing linksHashtagNewsHashtagCMN Weekly

News: CMN Weekly (26 May 2023) - Your Weekly CRISPR Medicine News
News: CMN Weekly (26 May 2023) - Your Weekly CRISPR Medicine News
CLINICAL TRIALS
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Huntington's Disease, (NCT05032196)
Sponsors:
Wave Life Sciences Ltd.
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine